Measurement of AQCmax of five different ophthalmic solutions and discussion of its new application

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 4, 2009, Pages 351-355

  Fukuda, Masamichi ^a   Sasaki, Hiroshi ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; TOSUFLOXACIN; TOSUFLOXACIN TOSILATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG INSTILLATION; DRUG PENETRATION; EXPERIMENTAL RABBIT; MALE; MAXIMUM AQUEOUS CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TIME TO MAXIMUM AQUEOUS CONCENTRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; AQUEOUS HUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, BACTERIAL; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; MALE; MICROBIAL SENSITIVITY TESTS; OPHTHALMIC SOLUTIONS; RABBITS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 68549111025     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0032     Document Type: Article

References (26)

1. Fukuda, M., and Sasaki, K. General purpose antimicrobial ophthalmic solutions evaluated using new pharmacokinetic parameter of maximum drug concentration in aqueous. Jpn. J. Ophthalmol. 46:384-390, 2002. (Pubitemid 35286589)
2. Sasaki, K., Mitsui, Y., Fukuda, M., et al. Intraocular penetration mode of five fluoroquinolone ophthalmic solutions evaluated by the newly proposed parameter of AQCmax. Atarashii Ganka (J Eye). 12:787-790, 1995.
3. Mitsui, Y., Oishi, M., Sasaki, K., et al. Proposal of AQCmax as a pharmacokinetic parameter for ophthalmic solutions. Atarashii Ganka (J Eye). 12:783-786, 1995.
4. Nishino, T., and Otsuki. In vitro and in vivo antibacterial activity of moxifloxacin, a novel quinolone antibacterial agent. Jpn. J. Chemother. 53:1-15, 2005. (Pubitemid 43056133)
5. Tanaka, K., and Watanabe, K. In vitro antibacterial activity of moxifloxacin against anaerobic and facultative bacteria. Jpn. J. Chemother. 53:21-26, 2005. (Pubitemid 43056135)
6. Yamada, M., Hatou, S., and Yoshida, J. In vitro susceptibilities of bacterial isolated from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin. Eye Contact Lens. 34:109-112, 2008. (Pubitemid 351355188)
7. Kowalski, R.P., Dhaliwal, D.K., Karenchak, L.M., et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levo- floxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am. J. Ophthalmol. 136:500-505, 2003.
8. Li, X., Zhao, X., and Drlica, K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levo- floxacin. Antimicrob. Agents Chemother. 46:522-524, 2002. (Pubitemid 34087206)
9. Zhao, X., and Drlica, K. Restricting the selection of antibioticresistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185:561-565, 2002. (Pubitemid 34142821)
10. Fukuda, M. Please teach it about AQCmax (aqueous concentration max). Atarashii Ganka (J Eye) 17:37-40, 2000.
11. Fukuda, M., and Takahashi, N. Intraocular penetration of gati- floxacin ophthalmic solution in rabbit eyes-calculation of maximum aqueous concentration (AQCmax). Atarashii Ganka (J Eye). 21:1109-1112, 2004.
12. Fukuda, M., Inoue, A., Sasaki, K., et al. The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. Jpn. J. Ophthalmol. 48:93-96, 2004. (Pubitemid 38453779)
13. Hariprasad, S.M., Blinder, K.J., Shah, G.K., et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch. Ophthalmol. 123:39-44, 2005. (Pubitemid 40105427)
14. Zhanel, G., and Noreddin, A. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr. Opin. Pharmacol. 1:459-463, 2001. (Pubitemid 33593833)
15. McCulley, J.P., Caudle, D., Aronowicz, J.D., et al. Fourthgeneration fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 113:955-959, 2006. (Pubitemid 43795230)
16. Levine, J.M., Noecker, R.J., Lane, L.C., et al. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J. Cataract Refract. Surg. 30:2177-2182, 2004. (Pubitemid 39330678)
17. Yagci, R., Oflu, Y., Dincel, A., et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye. 21:990-994, 2007. (Pubitemid 47071612)
18. Katz, H.R., Masket, S., Lane, S.S., et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea. 24:955-958, 2005. (Pubitemid 41688529)
19. Robertson, S.M., Curtis, M.A., Schlech, B.A., et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv. Ophthalmol. 50:S32-S45, 2005. (Pubitemid 41657597)
20. Mather, R., Stewart, J.M., Prabriputaloong, T., et al. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am. J. Ophthalmol. 138:554-559, 2004. (Pubitemid 39420481)
21. Alfonso, E., and Crider, J. Ophthalmic infections and their antiinfective challenges. Surv. Ophthalmol. 50:S1-S6, 2005. (Pubitemid 41657594)
22. Langlois, M.H., Montagut, M., Dubost, J.P., et al. Protonation equilibrium and lipophilicity of moxifloxacin. J. Pharm. Biomed. Anal. 37:389-393, 2005.
23. Fukuda, M., and Sasaki, K. In vitro topically applied fluoroquinolone penetration into the anterior chamber. J. Jpn. Ophthalmol. Soc. 99:532-536, 1995.
24. Schlech, B.A., and Alfonso, E. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Surv. Ophthalmol. 50:S7-S15, 2005. (Pubitemid 41657595)
25. Blondeau, J.M., Zhao, X., Hansen, G., et al. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438, 2001. (Pubitemid 32105277)
26. Metzler, K., Hansen, G.M., Hedlin, P., et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin susceptible and -resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 24:161-167, 2004. (Pubitemid 38993695)